DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for Eric S. Sayers
36.58
+0.55 (1.53%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.35 - 36.99
52 week 15.04 - 49.83
Open 36.03
Vol / Avg. 693,073.00/1.04M
Mkt cap 2.74B
P/E     -
Div/yield     -
EPS -0.42
Shares 74.81M
Beta 0.43
Inst. own 106%
May 29, 2014
DEXCOM INC Annual Shareholder Meeting - 5:00PM EDT - Add to calendar
Apr 28, 2014
Q1 2014 DEXCOM INC Earnings Release (Estimated) Add to calendar
Mar 11, 2014
DEXCOM INC at Barclays Healthcare Conference
Mar 10, 2014
DEXCOM INC at ROTH Conference
Mar 4, 2014
DEXCOM INC at Raymond James Financial Inc Institutional Investors Conference
Feb 20, 2014
Q4 2013 DEXCOM INC Earnings Conference Call - Webcast
Feb 20, 2014
Q4 2013 DEXCOM INC Earnings Release
Feb 13, 2014
DEXCOM INC at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -5.03% -18.62%
Operating margin -4.45% -18.06%
EBITD margin - -13.69%
Return on average assets -8.97% -26.08%
Return on average equity -13.13% -37.00%
Employees 646 -
CDP Score - -

Address

6340 Sequence Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company�s sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.

Officers and directors

Jonathan T. Lord M.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Terrance H. Gregg Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Jess Roper Chief Financial Officer, Vice President
Age: 48
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 41
Bio & Compensation  - Reuters
Richard B. Doubleday Senior Vice President - Worldwide Sales
Age: 50
Bio & Compensation  - Reuters
Andrew K. Balo Senior Vice President - Clinical and Regulatory Affairs
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jeffrey C. Moy Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Jorge A. Valdes Chief Technical Officer
Age: 45
Bio & Compensation  - Reuters
John D. Lister General Counsel, Vice President - Human Resources
Age: 38
Bio & Compensation  - Reuters